| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 355.58% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 09/15/2022 | 355.58% | Canaccord Genuity | → $20 | Initiates Coverage On | → Buy |
| 08/17/2022 | 127.79% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 150.57% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 127.79% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 173.35% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 537.81% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -65.83% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -43.05% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -76.08% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -31.66% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 287.24% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 150.57% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
What is the target price for KemPharm (KMPH)?
The latest price target for KemPharm (NASDAQ: KMPH) was reported by Cantor Fitzgerald on November 17, 2022. The analyst firm set a price target for $20.00 expecting KMPH to rise to within 12 months (a possible 355.58% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for KemPharm (KMPH)?
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by Cantor Fitzgerald, and KemPharm initiated their overweight rating.
When is the next analyst rating going to be posted or updated for KemPharm (KMPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
Is the Analyst Rating KemPharm (KMPH) correct?
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a initiated with a price target of $0.00 to $20.00. The current price KemPharm (KMPH) is trading at is $4.39, which is within the analyst's predicted range.